Updated decay data evaluation for 68Ga

Determination of the Terbium-152 Half-Life from Mass-Separated Samples from CERN-ISOLDE and Assessment of the Radionuclide Purity

“…Recent in-vivo PET imaging studies have shown reasonable PET imaging performance, though spatial resolution can be poor due to the relatively high positron energy and interfering gamma rays (Müller et al, 2012(Müller et al, , 2016. In these studies, some advantages were identified over other PET radioisotopes, such as 68 Ga (T 1/2 = 67.83(20) min (Kuzmenko, 2019)), due to the possibility of longer imaging periods and potentially preferable to 89 Zr (T 1/2 = 78.361(25) h (Fenwick et al, 2020)) or 64 Cu (T 1/2 = 12.7004 (20) h (Bé et al, 2011)) due to chemistry constraints requiring different chelators for coordination with existing radiotherapeutic radionuclides such as 177 Lu and 166 Ho. First in-human PET/CT studies of 152 Tb-DO-TATOC and 152 Tb-PSMA have been reported for neuroendocrine tumours and prostate cancer, respectively (Baum et al, 2017;Müller et al, 2019).…”